Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | PTGIR | P43119 | 5/20 | 0.42 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.41 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5724902 | 0.85 | PTGIR (0.38) | HTTALDH1A1PTGIRPTGDRNR3C2 | |
| SCHEMBL5031160 | 0.82 | ALDH1A1 (0.42) | HTTNPC1ALDH1A1POLBRAB9A | |
| SCHEMBL11541242 | 0.81 | ALDH1A1 (0.63) | HTTNPC1ALDH1A1POLBRAB9A | |
| SCHEMBL10364096 | 0.81 | HDAC3 (0.44) | ALDH1A1ESR1ESR2KCNH2 | |
| SCHEMBL107191 | 0.81 | FOLH1 (0.52) | HTTALDH1A1AGTR2FOLH1 | |
| SCHEMBL8243336 | 0.79 | ALDH1A1 (0.41) | HTTALDH1A1POLBKMT2ANPSR1 | |
| SCHEMBL8245878 | 0.78 | NPC1 (0.64) | HTTNPC1ALDH1A1POLBRAB9A | |
| SCHEMBL5319072 | 0.76 | ESR1 (0.43) | HTTNPC1ALDH1A1POLBRAB9A | |
| SCHEMBL1443806 | 0.76 | TP53 (0.52) | HTTNPC1ALDH1A1POLBRAB9A | |
| SCHEMBL10698132 | 0.74 | POLB (0.39) | HTTNPC1ALDH1A1POLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0256909-B1 | N,N-BIS-(4-FLUOROPHENYL) CARBAMOYL ACETOHYDROXAMIC ACID AND PHARMACEUTICAL COMPOSITION CONTAINING IT | LABORATOIRE L. LAFON Société anonyme dite: (FR) | 1990-01-31 | — | — | EP | claimed |
| EP-0256909-A1 | N,N-bis-(4-fluorophenyl) carbamoyl acetohydroxamic acid and pharmaceutical composition containing it | LABORATOIRE L. LAFON Société anonyme dite: (FR) | 1988-02-24 | — | — | EP | claimed |
| US-8883816-B2 | Fused and spirocycle compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883816-B2 | Fused and spirocycle compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20140045875-A1 | Fused and Spirocycle Compounds and the Use Thereof | PURDUE PHARMA L.P. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045875-A1 | Fused and Spirocycle Compounds and the Use Thereof | PURDUE PHARMA L.P. (US) | 2014-02-13 | — | — | US | disclosed |
| US-8546417-B2 | Fused and spirocycle compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546417-B2 | Fused and spirocycle compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120309778-A1 | Fused and Spirocycle Compounds and the Use Thereof | PURDUE PHARMA L.P. (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120309778-A1 | Fused and Spirocycle Compounds and the Use Thereof | PURDUE PHARMA L.P. (US) | 2012-12-06 | — | — | US | disclosed |
| US-8193208-B2 | Fused and spirocycle compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193208-B2 | Fused and spirocycle compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20090118319-A1 | Fused and Spirocycle Compounds and the Use Thereof | EURO-CELTIQUE S.A. (LU) | 2009-05-07 | — | — | US | disclosed |
| US-20090118319-A1 | Fused and Spirocycle Compounds and the Use Thereof | EURO-CELTIQUE S.A. (LU) | 2009-05-07 | — | — | US | disclosed |
| WO-2007028638-A1 | FUSED AND SPIROCYCLE COMPOUNDS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2007-03-15 | — | — | WO | disclosed |
| EP-0256909-B1 | N,N-BIS-(4-FLUOROPHENYL) CARBAMOYL ACETOHYDROXAMIC ACID AND PHARMACEUTICAL COMPOSITION CONTAINING IT | LABORATOIRE L. LAFON Société anonyme dite: (FR) | 1990-01-31 | — | — | EP | disclosed |
| EP-0256909-A1 | N,N-bis-(4-fluorophenyl) carbamoyl acetohydroxamic acid and pharmaceutical composition containing it | LABORATOIRE L. LAFON Société anonyme dite: (FR) | 1988-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309778-A1 | Fused and Spirocycle Compounds and the Use Thereof | CACNA1A, CACNA1E, CACNA1C | HTT 2178/4885NPC1 443/4885ALDH1A1 1044/4885 |
| US-20090118319-A1 | Fused and Spirocycle Compounds and the Use Thereof | CACNA1A, CACNA1E, CACNA1C | HTT 2178/4885NPC1 443/4885ALDH1A1 1044/4885 |
| US-20140045875-A1 | Fused and Spirocycle Compounds and the Use Thereof | CACNA1A, CACNA1E, CACNA1C | HTT 2178/4885NPC1 443/4885ALDH1A1 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.